Presentation is loading. Please wait.

Presentation is loading. Please wait.

Administration of gonadotropin-releasing hormone antagonist from day 1 of stimulation in in vitro fertilization  Efstratios M Kolibianakis, M.D., Kostas.

Published byありあ かやぬま Modified over 5 years ago

Similar presentations

Presentation on theme: "Administration of gonadotropin-releasing hormone antagonist from day 1 of stimulation in in vitro fertilization  Efstratios M Kolibianakis, M.D., Kostas."— Presentation transcript:

1 Administration of gonadotropin-releasing hormone antagonist from day 1 of stimulation in in vitro fertilization  Efstratios M Kolibianakis, M.D., Kostas Zikopoulos, M.D., Ph.D., Johan Smitz, M.D., Ph.D., Michel Camus, M.D., Herman Tournaye, M.D., Ph.D., Andre C Van Steirteghem, M.D., Ph.D., Paul Devroey, M.D., Ph.D.  Fertility and Sterility  Volume 82, Issue 1, Pages (July 2004) DOI: /j.fertnstert

2 FIGURE 1 Serum LH, FSH, E2, and P levels on days 1, 3, 6, 8, and 9 of stimulation with rec-FSH and GnRH antagonists. The 95% confidence interval is also shown. Kolibianakis. Initiation of GnRH antagonist on day 1 in IVF. Fertil Steril 2004. Fertility and Sterility  , DOI: ( /j.fertnstert )

Download ppt "Administration of gonadotropin-releasing hormone antagonist from day 1 of stimulation in in vitro fertilization  Efstratios M Kolibianakis, M.D., Kostas."

Similar presentations

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome  Madelon van Wely, Ph.D.,

Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome  Madelon van Wely, Ph.D.,
Elevated serum progesterone-to-estradiol ratio during gonadotropin stimulation for intrauterine insemination or in vitro fertilization is not associated.

Elevated serum progesterone-to-estradiol ratio during gonadotropin stimulation for intrauterine insemination or in vitro fertilization is not associated.
Clinical outcome of non–hCG-primed oocyte in vitro maturation treatment in patients with polycystic ovaries and polycystic ovary syndrome  Michel De Vos,

Clinical outcome of non–hCG-primed oocyte in vitro maturation treatment in patients with polycystic ovaries and polycystic ovary syndrome  Michel De Vos,
Oral contraceptive pill pretreatment in ovarian stimulation with GnRH antagonists for IVF: a systematic review and meta-analysis  George Griesinger, M.D.,

Oral contraceptive pill pretreatment in ovarian stimulation with GnRH antagonists for IVF: a systematic review and meta-analysis  George Griesinger, M.D.,
Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study  Thi.

Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study  Thi.
Developmental capacity of in vitro–matured human oocytes retrieved from polycystic ovary syndrome ovaries containing no follicles larger than 6 mm  Luis.

Developmental capacity of in vitro–matured human oocytes retrieved from polycystic ovary syndrome ovaries containing no follicles larger than 6 mm  Luis.
Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration  Jean-noêl Hugues,

Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration  Jean-noêl Hugues,
Elevated serum progesterone-to-estradiol ratio during gonadotropin stimulation for intrauterine insemination or in vitro fertilization is not associated.

Elevated serum progesterone-to-estradiol ratio during gonadotropin stimulation for intrauterine insemination or in vitro fertilization is not associated.
Oral contraceptive pretreatment significantly reduces ongoing pregnancy likelihood in gonadotropin-releasing hormone antagonist cycles: an updated meta-analysis 

Oral contraceptive pretreatment significantly reduces ongoing pregnancy likelihood in gonadotropin-releasing hormone antagonist cycles: an updated meta-analysis 
The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition  Lorraine Dennerstein,

The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition  Lorraine Dennerstein,
Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,

Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,
Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization–intracytoplasmic.

Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization–intracytoplasmic.
Value of the serum estradiol level for preventing ovarian hyperstimulation syndrome: a retrospective case control study  Arianna D'Angelo, M.D., Rachel.

Value of the serum estradiol level for preventing ovarian hyperstimulation syndrome: a retrospective case control study  Arianna D'Angelo, M.D., Rachel.
Effects and clinical significance of GnRH antagonist administration for IUI timing in FSH superovulated cycles: a meta-analysis  Ioannis P. Kosmas, M.D.,

Effects and clinical significance of GnRH antagonist administration for IUI timing in FSH superovulated cycles: a meta-analysis  Ioannis P. Kosmas, M.D.,
No association between endogenous LH and pregnancy in a GnRH antagonist protocol: part II, recombinant FSH  George Griesinger, Daniel B. Shapiro, Efstratios.

No association between endogenous LH and pregnancy in a GnRH antagonist protocol: part II, recombinant FSH  George Griesinger, Daniel B. Shapiro, Efstratios.
Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.

Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.
The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation.

The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation.
A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer 

A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer 
Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization.

Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization.

Similar presentations

Ads by Google